A recent study posted to the bioRxiv* preprint server assessed the mechanism by which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron and Alpha variants of concern (VOCs) inhibit ...
Researchers have identified a new mechanism that underlies dopamine release in the brain. The research, conducted in mice, shows that another chemical messenger called acetylcholine can trigger the ...
The opioid epidemic in the United States has exacted an incalculable toll on individuals and communities, creating an urgent need for alternative painkillers. The search for non-opioid treatments is ...
The new report suggests patients with acetylcholine receptor (AChR) antibody titers above 8.11 nmol/L were at higher risk of conversion. Antibody titers in patients with acetylcholine receptor (AChR) ...
Inebilizumab-cdon is approved for anti-acetylcholine receptor and anti-muscle specific tyrosine kinase antibody–positive generalized myasthenia gravis, based on MINT trial results. Inebilizumab gains ...
FDA Approves Amgen's Uplizna for Generalized Myasthenia Gravis With Positive AChR or MuSK Antibodies
The FDA’s approval of Uplizna for antibody-positive generalized myasthenia gravis introduces a twice-yearly CD19-targeted therapy option for the rare autoimmune condition. The FDA has approved Amgen’s ...
Amgen (AMGN) announced that the FDA has approved Uplinza, inebilizumab-cdon, for the treatment of generalized myasthenia gravis, gMG, in adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback